30.03.2022 • News

Global Sciences Buys Pure BioPlastics

Global Sciences, a Canadian multinational consumer goods company that also specializes in cannabidiol (CBD) products, has executed a binding letter of intent to buy Pure BioPlastics from Pure Vision Technology. The move follows six months of due diligence and discovery between the companies.

Following the transaction’s closure, which is expected on or before Apr. 15, Global Sciences will create a Bio-based Technologies division, headed by Pure BioPlastics founder Ed Lehrburger.

Based in Fort Lupton, Colorado, Pure BioPlastics was initially established to scale up PureVision’s patented continuous countercurrent reactor (CCR) technology that converts non-food biomass such as hemp, corn stalks, switchgrass and wheat straw into pulp, lignin and sugars.

The technology has been proven at pilot-scale and Global Sciences plans to fund the scale-up of processing capability from 0.5 t/d to 8 t/d within 16-24 months. Ultimately, the firm intends to develop a 60 t/d CCR-based biorefinery, capable of future expansion.

Because the bio-based plastic created by the technology is 100% sourced from plant material, the composition of the principal product can be manipulated to control the timeline of the plastic degradation, Global Sciences said, adding that this characteristic would support a wide variety of “designer” biodegradable products, including straws, lids and plastic components for cars and aircraft.

Author: Elaine Burridge, Freelance Journalist

 

(c) Vardan Papikyan
(c) Vardan Papikyan

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read